Skip to content

Author

Azadeh Nasuhidehnavi

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Oct 2026

Enlicitide: The First Oral PCSK9i for Lowering Low-Density Lipoprotein Cholesterol.

OBJECTIVE This article describes pharmacology, pharmacokinetics, safety, and efficacy data of enlicitide, the first Food and Drug Administration (FDA)-approved oral proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i). DATA SOURCES PubMed, Embase, Web of Science, and Cochrane were searched through July 17...

Rachel C. Lucas, M. Lussier, Azadeh Nasuhidehnavi et al. · 0 citations
Review Open access Jul 2026

Chronic Infection and Cardiac Aging: a New Perspective on Pathogen-Associated Cardiomyopathy.

By characterizing chronic infection as a modifiable driver of biological aging, this work can prioritize anti-infective strategies as essential components of cardiovascular longevity and geriatric care.

Noah Walsh, Sophia DeCesare, Kavisha Patel et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.